Association de Recherche Clinique en Rhumatologie Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2003
NCT00439283
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

infliximab (remicade) (1 trial)

naltrexone (revia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Spondylitis (Phase 3)

Spondylitis, Ankylosing (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2